Last $133.61 USD
Change Today +0.22 / 0.16%
Volume 134.1K
IDXX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

idexx laboratories inc (IDXX) Snapshot

Open
$133.74
Previous Close
$133.39
Day High
$134.22
Day Low
$132.58
52 Week High
07/2/14 - $137.68
52 Week Low
07/23/13 - $91.03
Market Cap
6.9B
Average Volume 10 Days
207.8K
EPS TTM
$3.56
Shares Outstanding
51.3M
EX-Date
--
P/E TM
37.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for IDEXX LABORATORIES INC (IDXX)

idexx laboratories inc (IDXX) Related Bloomberg News

View More Bloomberg News

idexx laboratories inc (IDXX) Related Businessweek News

No Related Businessweek News Found

idexx laboratories inc (IDXX) Details

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company operates through Companion Animal Group, Water, Livestock and Poultry Diagnostics, Dairy, and OPTI Medical segments. The company primary offers point-of-care veterinary diagnostic products comprising instruments and consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; and practice management systems and services, and digital radiography systems used by veterinarians. It also provides biological materials testing and laboratory diagnostic instruments and services used by the biomedical research community; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; products that test milk for antibiotic residues and other contaminants; and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market. The company markets and sells its products through marketing, sales, and technical service groups, as well as independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

5,700 Employees
Last Reported Date: 02/18/14
Founded in 1983

idexx laboratories inc (IDXX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $784.6K
Executive Vice President
Total Annual Compensation: $396.2K
Executive Vice President
Total Annual Compensation: $396.2K
Executive Vice President
Total Annual Compensation: $396.2K
Vice President of Finance
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

idexx laboratories inc (IDXX) Key Developments

IDEXX Laboratories, Inc. with IDEXX Distribution, Inc., IDEXX Operations, Inc., IDEXX Reference Laboratories, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, and IDEXX Europe B.V. Enter into an Amended and Restated Credit Agreement

On June 18, 2014, IDEXX Laboratories, Inc. with IDEXX Distribution, Inc., IDEXX Operations, Inc., IDEXX Reference Laboratories, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, and IDEXX Europe B.V., each a wholly-owned subsidiary of the company, entered into an amended and restated credit agreement relating to a five-year unsecured revolving credit facility in the principal amount of $700 million, among the Borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and J.P. Morgan Europe Limited, as London agent. Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Credit Agreement. The Credit Agreement amends and restates that certain amended and restated credit agreement dated as of May 9, 2013 to extend the maturity to June 18, 2019 and to increase the aggregate commitments available for borrowing by the Borrowers to $700 million with the option to increase the aggregate commitments by $150 million, for an aggregate maximum of $850 million, subject to the Borrowers obtaining commitments from existing or new lenders and satisfying other conditions specified in the Credit Agreement. Borrowings under the Credit Agreement may be used for the general corporate purposes of the company and its subsidiaries. Borrowings under the Credit Agreement bear interest at a rate equal to, in each case at the company's option, for borrowings in United States Dollars, either a base rate, determined as the greater of the prime rate announced by JPMorgan Chase Bank, N.A. in New York, the Federal Funds Effective Rate plus 0.50% and the Adjusted LIBO Rate for a one-month Interest Period plus 1%, plus a margin rate ranging from 0.000% to 0.375% based on the company's consolidated leverage ratio, or a Libor rate determined as the rate appearing on Reuters Screen LIBOR01 Page on the Quotation Day for such Interest Period multiplied by a statutory reserve rate, plus a margin rate ranging from 0.875% to 1.375% based on the company's consolidated leverage ratio, for borrowings in Canadian Dollars, either a base rate determined as the greater of (i) the prime rate announced by JPMorgan Chase Bank, N.A., Toronto Branch and (ii) the sum of the yearly interest to which the one-month CDOR Rate is equivalent plus 1%, plus a margin rate ranging from 0.000% to 0.375% based on the company's consolidated leverage ratio, or the sum of the average rate for banker acceptances with a term equal in length to such Interest Period as displayed on CDOR page of the Reuters screen plus 0.05%, plus a margin rate ranging from 0.875% to 1.375% based on the company's consolidated leverage ratio, for borrowings in Euros, the percentage per annum displayed on the applicable page of the Reuters screen, plus a margin rate ranging from 0.875% to 1.375% based on the company's consolidated leverage ratio, for borrowings in Australian Dollars, the average bid rate on Reuters Screen BBSY Page for bills of exchange having a term equal to the length of such Interest Period, plus a margin rate ranging from 0.875% to 1.375% based on the company's consolidated leverage ratio and for borrowings in alternative currencies the Libor rate determined as the rate appearing on Reuters Screen LIBOR02 Page for such currency for such Interest Period, plus a margin rate ranging from 0.875% to 1.375% based on the company's consolidated leverage ratio.

IDEXX Laboratories, Inc. Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-10-2014 10:10 AM

IDEXX Laboratories, Inc. Presents at William Blair & Company's 34th Annual Growth Stock Conference, Jun-10-2014 10:10 AM. Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States. Speakers: Jonathan W. Ayers, Chairman, Chief Executive Officer and President.

IDEXX Laboratories Mulls Acquisitions

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) is looking for acquisitions. Brian Mckeon, Chief Financial Officer of IDEXX Laboratories said, "We may selectively add distribution capability as we have in the last year, and there may be some additions that we make to our technology portfolio. But over the last five years, I think we have averaged about $25 million a year in acquisitions spend. And I think going forward, I think you are likely to see kind of a similar, narrow range of how much capital we are going to be deploying on the acquisition front”.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDXX:US $133.61 USD +0.22

IDXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $47.46 USD -0.04
Hologic Inc $25.70 USD +0.22
Mettler-Toledo International Inc $251.28 USD +0.74
ResMed Inc $49.26 USD -0.33
Cooper Cos Inc/The $150.21 USD +1.38
View Industry Companies
 

Industry Analysis

IDXX

Industry Average

Valuation IDXX Industry Range
Price/Earnings 37.4x
Price/Sales 4.9x
Price/Book 13.4x
Price/Cash Flow 36.1x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDEXX LABORATORIES INC, please visit www.idexx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.